8-K: Champions Oncology Reports Q1 FY26 Results

Champions Oncology reported first-quarter fiscal 2026 revenue of $14.0 million and adjusted EBITDA of $60,000, alongside the appointment of Rob Brainin as CEO.

Summary

• Total revenue for the first quarter of fiscal 2026 was $14.0 million, a slight decrease from $14.1 million for the same period last year.
• Adjusted EBITDA significantly declined to $60,000 in Q1 FY26 from $2.0 million in Q1 FY25.
• The company reported a GAAP net loss of $466,000, or $(0.03) per share, for Q1 FY26, compared to a net income of $1.3 million, or $0.10 per share, in Q1 FY25.
• Cost of oncology revenue increased by 13.1% to $8.0 million, primarily due to higher outsourced lab services for radiolabeling work.
• Gross margin decreased to 43% from 50% in the prior year.
• Research and development expenses rose 43.2% to $2.1 million, reflecting greater investment in sequencing and related costs to develop the data licensing platform.
• Rob Brainin was appointed as the new Chief Executive Officer.
• The company ended the quarter with approximately $10.3 million in cash on hand and no debt.

Sentiment

Score: 4

Explanation: While the company reported a significant decline in profitability metrics (Adjusted EBITDA, net income, gross margin) and a slight revenue dip, management expressed optimism about sequential growth, strengthening core services, and traction in the data platform. The appointment of a new CEO and strategic investments in R&D for future growth, along with a strong balance sheet, provide some positive counterbalance to the poor quarterly financial performance.

Positives

• Rob Brainin was appointed as Chief Executive Officer to lead the next phase of growth.
• The core services business is strengthening and well-positioned for sustained growth.
• The emerging data platform is scaling and has shown encouraging traction with leading biopharma partners.
• The Corellia team continues to generate data demonstrating the potential of compounds in the pipeline.
• Management anticipates continued topline expansion and margin improvement in future quarters.
• The company maintains a strong balance sheet with approximately $10.3 million cash on hand and no debt.
• Net cash provided by operating activities was approximately $600,000 for the quarter.
• Data license revenue increased by $300,000.

Negatives

• Total revenue was slightly lower at $14.0 million compared to $14.1 million in the prior year's first quarter.
• Adjusted EBITDA significantly decreased to $60,000 from $2.0 million in Q1 FY25.
• Reported a loss from operations of $527,000 compared to income from operations of $1.3 million in Q1 FY25.
• GAAP net loss of $466,000 for Q1 FY26 compared to net income of $1.3 million in Q1 FY25.
• GAAP EPS decreased to $(0.03) from $0.10 in Q1 FY25.
• Cost of oncology revenue increased by 13.1% to $8.0 million.
• Gross margin declined to 43% from 50% in the prior year.
• Research and development expense increased by 43.2% to $2.1 million.
• Sales and marketing expense increased by 10.5% to $1.9 million.

Risks

• Forward-looking statements inherently involve risk and uncertainties, and actual results could differ materially from anticipated outcomes due to unforeseen factors.
• Reliance on outsourced lab services for radiolabeling work can cause variability in the cost of oncology revenue, though the company plans to mitigate this by migrating work in-house.

Future Outlook

Management anticipates continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for proprietary data offerings. The company plans to invest in key capabilities and strategic initiatives, including migrating outsourced lab work in-house to reduce costs and improve gross margins in coming quarters.

Management Comments

• "It is great to be joining Champions at such an exciting inflection point. Our core services business—the backbone of our company—is strengthening and well positioned for sustained growth. At the same time, we are scaling our emerging data platform, which has already shown encouraging traction with leading biopharma partners. These complementary growth engines give us the opportunity to deepen our scientific impact, deliver innovative solutions to patients and customers, and create durable long-term value for shareholders. In parallel, our Corellia team continues to generate data demonstrating the potential of the compounds in our pipeline. Over the coming quarters, I look forward to working closely with our talented team to sharpen our strategy, invest in key capabilities, and build on Champions culture of collaboration and scientific excellence." Rob Brainin, CEO.
• "We opened the fiscal year with $14 million in revenue and adjusted EBITDA of $60,000. While revenue was slightly lower than the first quarter of last year, we achieved solid sequential growth that met our expectations and provides a strong foundation for the year. As we move forward, we anticipate continued topline expansion and margin improvement driven by a healthy services pipeline and growing demand for our proprietary data offerings. Our financial discipline and focus on profitable growth give us the flexibility to invest in strategic initiatives that will position Champions for long-term success." David Miller, CFO.

Industry Context

Champions Oncology operates in the highly competitive and rapidly evolving translational oncology research sector. The company's focus on strengthening its core services and scaling its data platform aligns with broader industry trends towards integrated R&D solutions and data-driven drug discovery. The investment in R&D for the data licensing platform suggests a strategic move to capture value from proprietary data, a growing area of interest in biopharma for accelerating drug development and precision medicine.

Comparison to Industry Standards

• NA

Management Changes

Corporate Governance

Legal Proceedings

• NA

Related Party Transactions

• NA

Stakeholder Impact

• Shareholders: Potential for long-term value creation through strategic investments and growth engines, but short-term financial performance (loss, lower EBITDA) may impact sentiment.
• Employees: New CEO appointment may lead to strategic shifts and investment in key capabilities, potentially impacting roles and opportunities.
• Customers (Biopharma Partners): Continued focus on strengthening core services and scaling the data platform aims to deliver innovative solutions and deepen scientific impact.
• Suppliers (Outsourced Lab Services): Anticipated migration of radiolabeling work in-house suggests a potential reduction in reliance on external suppliers for these services.

Next Steps

• Sharpen strategy and invest in key capabilities under new CEO Rob Brainin.
• Migrate outsourced radiolabeling lab services in-house to reduce costs and improve gross margins in coming quarters.
• Continue to scale the emerging data platform.
• Generate further data demonstrating the potential of compounds in the Corellia pipeline.
• Host a conference call on September 15, 2025, at 4:30 p.m. EDT to discuss financial results.
• File Form 10-Q on September 15, 2025, for full financial details.

Key Dates

Recommendation

While the first-quarter financial results show a significant decline in profitability (Adjusted EBITDA, net income, gross margin) and a slight revenue dip, the company is undergoing a strategic transition with a new CEO, Rob Brainin, who brings a vision for strengthening core services and scaling the promising data platform. The company maintains a strong balance sheet with no debt and positive operating cash flow. The planned migration of outsourced lab work in-house is a positive step towards margin improvement. Given the mixed results—poor current performance but strategic initiatives and leadership changes aimed at future growth—a 'hold' recommendation is appropriate. Investors should monitor the execution of the new strategy and the impact of investments in the data platform and in-house lab capabilities in subsequent quarters before making further investment decisions.

Keywords

Oncology Research, Translational Oncology, Biopharma, SEC Filing, Financial Results, Q1 Earnings, CSBR, Patient-Derived Xenograft, PDX Models, Data Platform, Biotechnology, Drug Discovery